ClinicalTrials.gg
Sign In
Status unknownNCT03886298Updated Jul 8, 2019

Radiofrequency Splanchnic Denervation Versus Retrocrural Neurolytic Celiac Block for Pancreatic Cancer Pain

An interventional study of radiofrequency splanchnic denervation and retrocrural celiac denervation in Chronic Pain, sponsored by Assiut University. Status unknown at 1 site in Egypt. Open to participants aged 16 Years to 90 Years. Per ClinicalTrials.gov, last updated 2019-07-08.

Sponsored by Assiut University · Not applicable, Interventional, and Treatment

The sponsor has not verified this record recently (last verified Jul 2019), so the status shown — last known as Recruiting — may be out of date.
Phase
Not applicable
Study type
Interventional
Enrollment
60
Allocation
Randomized
Ages
16 Years to 90 Years
Sex
All
01

Study summary

The investigators will evaluate the analgesic efficacy of radiofrequency splanchnic nerve denervation versus neurolytic retrocrural celiac denervation for patients with abdominal pain due to cancer pancreas

02

Conditions studied

  • Chronic Pain

Browse trials for

03

In context

Chronic Pain

2,999 studies on the registry are indexed under Chronic Pain; 706 are open to participants now.

This study's planned enrollment of 60 is close to the median of 60 across 2,209 interventional studies indexed under Chronic Pain.

Browse Chronic Pain studies →

Lead sponsor

Assiut University is the lead sponsor of 5,050 studies on the registry; 2,174 are open to participants now.

Of its 14 completed or terminated interventional studies of FDA-regulated products, 0 (0%) have results posted.

Browse Assiut University studies →

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
16 Years to 90 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • patients with abdominal pain due to cancer pancreas

Exclusion criteria

Exclusion Criteria:

  • coagulopathy
  • infection at site of the procedure
05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Single (Outcomes assessor)
Enrollment
60 participants (estimated)

Study arms

  • Experimental
    radiofrequency splanchnic denervation

    Procedure: radiofrequency splanchnic denervation

  • Active comparator
    retrocrural celiac denervation

    Procedure: retrocrural celiac denervation

Interventions

  • Procedureradiofrequency splanchnic denervation

    the authors will denervate the splanchnic nerves via radiofrequency

  • Procedureretrocrural celiac denervation

    the authors will denervate the splanchnic nerves in the retrocrural space via injection of alcohol

06

What researchers measure

Primary outcomes

  1. the percentage of patients that gain more than 50% reduction of their pain on VAS pain score

    VAS pain scale is a tool for measurement of pain intensity scored from 0 to 10 in which 0 + no pain and 10 + the worst pain immaginable

    Time frame: 6 months postoperatively

07

Study locations

1 of 1 sites recruiting
  • Diab
    Asyut, Assuit 71515, Egypt
    Recruiting
08

References and documents

Individual participant data

Plan to share: Undecided

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Apr 2019 (actual). Primary completion is estimated for Apr 2020, 12 months after the start.

Of 1,209 non-industry interventional studies with no phase under Chronic Pain, half reached primary completion within 21 months of starting (the median), counting those still running; a quarter within 9 and three quarters within 39. This study's planned 12 months is below that.

Counting every sponsor, half of 1,296 studies reached it within 21 months; a quarter within 9 and three quarters within 39.

How these figures are worked out, and which studies are left out of them.

Registered
Mar 20, 2019
First posted
Mar 22, 2019
StartActual
Apr 10, 2019
Primary completionEst.
Apr 10, 2020
CompletionEst.
Jun 10, 2020
Last update
Jul 8, 2019
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jul 8, 2019, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT03886298
Lead sponsor
Assiut University
Responsible party
Diab Fuad Hetta (Principle investigator, Assiut University) — Principal investigator
First posted
Mar 22, 2019
Start date
Apr 10, 2019
Primary completion
Apr 10, 2020 (estimated)
Completion
Jun 10, 2020 (estimated)
Last update
Jul 8, 2019

Oversight

FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is status unknown, as verified in Jul 2019. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Other studies in this condition

Chronic Pain →

Other studies from this sponsor

Assiut University →

Start the discussion